PDCD1 and posterior cortical atrophy: Subsequently, clinical studies of pembrolizumab, another anti-PD-1 monoclonal antibody, in mCRPC patients were ineffective, indicating that the application of PD-1 inhibitors as single agents and use of PD-L1 expression as a marker to establish sensitivity to PD-1 blockade therapy are insufficient to treat advanced PCa.17